

Letter to the Editor

Magnetic resonance venography after cesarean-section delivery



Dear Editor,

Venous thromboembolism (VTE) constitutes the leading cause of maternal mortality in the developed world.¹⁻⁴ The incidence of confirmed VTE during pregnancy and puerperium ranges from 0.5 to 3.0 per 1,000 pregnancies, representing 5- to 10-fold increased risk when compared with age-matched non-pregnant women.^{3,5} Pelvic vein thrombosis (PVT) is an important cause of VTE in the post-partum period, although few studies have investigated its incidence and clinical relevance.^{6,7} Furthermore, studies of VTE in the obstetrical population in the developing world are scarce⁸ or missing, in the case of PVT. The aim of this study was to evaluate the role of magnetic resonance venography (MRV) to detect PVT in women after Cesarean (C)-section delivery. To investigate this, we performed pelvic MRV within seven days after delivery and followed women in the postpartum period.

This was a prospective cohort study. The inclusion criteria were women older than 18 years, who underwent C-section delivery at the Obstetrical Unit of University Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. The exclusion criteria consisted of women who received anticoagulation during pregnancy, had contraindications to MRV and/or who were critically ill. The study was approved by local research Ethical Committee.

We collected information on socio-demographic, clinical data and risk factors for VTE during interview and from medical charts using a structured questionnaire. Women were included consecutively and followed by telephone interview every 30 days until 100 days post-partum. All women underwent a pelvic MRV, which was performed between day 0 and 7 after delivery. Pelvic MRV was performed on a 1.5-T scanner without contrast (Signa Excite, General Electric, Milwaukee, USA). The sequences consisted of gradient-echo (FIESTA) in axial/coronal plans and a 3D Time of Flight (TOF) angiography with arterial flow suppression and maximum intensity projection (MIP) reconstructions for assessment of vein patency. We defined PV as external iliac veins, internal iliac veins, common iliac veins, ovarian veins and inferior vena cava.

Suggestive PVT was considered when there were filling defects, presence of collateral veins, vessel irregularities or vessel narrowing. The presence of venous enlargement and signs of perivascular inflammation suggested recent thrombus. Two experienced radiologists blindly and independently adjudicated MRV and disagreements were resolved by a third observer. Women presenting filling defects on MRV repeated it after 12 weeks.

A total of 64 women were included, of whom 14 (22%) withdrew the informed consent after inclusion but before the performance of MRV. The final cohort comprised 50 women, median age 26 years (interquartile range [IQR], 22-32) (Table 1).

Median age of excluded group was 26 years (IQR, 20 - 33). A total of 4/50 women (8.0%; 95% CI, 3.2 % - 18.8 %) had MRV findings suggestive of filling defects in the postpartum period of whom 1 had no risk factor for VTE and 3 had one risk factor each (Figure 1, Table 2). The location of the potential filling defect varied (Table 2). All filling defects were semi-occlusive. All women were asymptomatic and none received anticoagulation. Agreement rate between the two radiologists was 100%.

The green arrows show filling defects in the pelvic veins.

RICV, Right Iliac Common Vein; LICV, Left Iliac Common Vein; LEIV, Left External Iliac Vein. Coronal (A and B), Axial (C and D)

A total of 49 out of 50 women (98%) were followed by telephone interview at 30, 60 and 90 days. The totality of women without filling defects by MRV did not report any complications during follow-up. The four subjects presenting with filling defects repeated the MRV at 116 –126 days after the first MRV showing no filling defects in the PV. They reported no symptoms/signs of VTE or other complications during the follow-up.

Few studies have investigated PVT after C-section⁷ and post-vaginal delivery.⁶ Both studies revealed a high rate of definitive PVT by MRV after C-section (46 %) in women with moderate to high risk for VTE⁷ and post-vaginal delivery (30 %) in women with low risk for VTE.⁶ In corroboration with our study, none of the thrombi was occlusive in the study by Roger et al.⁷ However, these authors did not report follow-up

Table 1 – Characteristics of the subjects included in the study.

Characteristics	n = 50
Median age (IQR)	26 (22-32)
Immobilization, n (%)	3 (11.5)
Obesity, n (%)	1 (3.8)
Multiparity, n (%)	5 (19.2)
CPOD or pulmonary hypertension, n (%)	1 (3.8)
Cardiovascular disease, n (%)	5 (19.2)
Preeclampsia or eclampsia, n (%)	3 (11.5)
Current twin pregnancy, n (%)	3 (11.5)
Infection during delivery or puerperium, n (%)	1 (3.8)
Traumatic or modification of delivery mode, n (%)	7 (26.9)
Sickle cell disease, n (%)	2 (7.7)
Current smoking, n (%)	2 (7.7)

N, number; IQR, interquartil range; VTE, venous thromboembolism; CPOD, chronic pulmonary obstructive disease.

of included women or repetition of the MRV in women with suspected PVT. To our concern, this is the first study reporting follow-up of women with suspected PVT after C-section.

In contrast with reported studies,^{6,7} we found filling defects in the PV in a less proportion of women after C-section delivery (8%) and none developed symptomatic PVT or other form of VTE. The encountered filling defects disappeared during the follow-up. These results suggest that either




Figure 1 – Magnetic resonance venography of pelvic veins showing filling defects.

Table 2 – Characteristics of the subjects presenting with filling defects by magnetic resonance venography of the pelvic veins.

Study Reg.	Age (y)	Risk factors for VTE	MRV findings
23	23	None	LEIV; Semi-occlusive
27*	19	Urgent modification of delivery mode	RCIV; Semi-occlusive
28	39	Age \geq 35 y	RCIV; Semi-occlusive
29*	27	Sickle cell disease	BCIV; Semi-occlusive

* Also had hypertension. Reg., Registry; y, year; MRV, Magnetic Resonance venography; LEIV, Left External Iliac Vein; RCIV, Right Common Iliac Vein; LCIV, Left Common Iliac Vein; BCIV, Both Common Iliac Veins, VTE, venous thromboembolism.

semi-occlusive PVT might be a thrombotic condition without clinical consequence,⁹ such as it is in the case of distal DVT of the legs or that the filling defects identified are artefactual due to extravascular compression mainly by an increased uterine volume, anatomical distortions, or other image defect which could resemble PVT. James has also suggested that thrombosis of PV could be part of a physiologic process to interrupt blood flow at the placental site and facilitate placental involution.⁹ However, we consider that this is a strong statement to define those filling defects as thrombi.

Our study poses limitations worth mentioning. Firstly, participants included in our study may not represent the overall population of pregnant women, once our hospital has a reference obstetrical unit for high-risk pregnancies. This could, therefore, introduced a selection bias. Secondly, since the study has been performed in one hospital, this reduces the generalizability of our findings.

In conclusion, we found filling defects in the PV in 8% of women after C-section delivery and none developed symptomatic PVT or other form of VTE. Further studies should be directed towards establishing baseline MRV findings in the immediate postpartum period in larger cohorts of women, to establish better estimates of the true population incidence of PVT, assess its natural history and to delineate how long filling defects (or thrombi) remain visible in the pelvis after delivery.

Conflicts of interest

The authors stated that they had no interests that might be perceived as posing a conflict or bias.

Acknowledgements

The authors thank the participants, MRI technologists, radiologists and the nursing team of the Obstetrics Unit, University Hospital, Universidade Federal de Minas Gerais.

This study was supported by FAPEMIG, grant number [EFP00001296](#) and CNPq (PIBIC)

REFERENCES

1. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American college of chest physicians evidence-based clinical practice guidelines. *Chest*. 2008;133:844S–86S.
2. Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 1991-1997. *Obstet Gynecol*. 2003;101:289–96.
3. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med*. 2005;143:697–706.
4. Sullivan EA, Ford JB, Chambers G, Slaytor EK. Maternal mortality in Australia, 1973-1996. *Aust N Z J Obstet Gynaecol*. 2004;44:452–7.
5. Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. *Obstet Gynecol*. 1999;94:730–4.
6. Khalil H, Avruch L, Olivier A, Walker M, Rodger M. The natural history of pelvic vein thrombosis on magnetic resonance venography after vaginal delivery. *Am J Obstet Gynecol*. 2012;206:356. e1-4.
7. Rodger MA, Avruch LI, Howley HE, Olivier A, Walker MC. Pelvic magnetic resonance venography reveals high rate of pelvic vein thrombosis after cesarean section. *Am J Obstet Gynecol*. 2006;194:436–7.
8. Gader AA, Haggaz AE, Adam I. Epidemiology of deep venous thrombosis during pregnancy and puerperium in sudanese women. *Vasc Health Risk Manag*. 2009;5:85–7.
9. James AH. The natural history of pelvic vein thrombosis: the natural history of involution? *Am J Obstet Gynecol*. 2012;206:276–7.

Gustavo H. Romani Magalhães , Daniel Dias Ribeiro ,
Suely Meireles Rezende *

Universidade Federal de Minas Gerais (UFMG), Belo Horizonte,
MG Brazil

*Corresponding author at: Faculty of Medicine, Universidade Federal de Minas Gerais, Av Alfredo Balena 190, room 255, Belo Horizonte, MG, Brazil.

E-mail address: srezende@ufmg.br (S.M. Rezende).

Available online 28 August 2022

<https://doi.org/10.1016/j.htct.2022.07.004>
2531-1379/

© 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).